Every research peptide in QSC’s catalog is produced by solid-phase peptide synthesis (SPPS) — the same technology used in pharmaceutical peptide manufacturing, Nobel Prize-winning chemistry developed by Merrifield in 1963. Understanding how SPPS works helps researchers understand why purity verification matters, what deletion sequences are, and what direct manufacturing means vs reselling.
What Is Solid-Phase Peptide Synthesis?
Solid-phase peptide synthesis (SPPS) is the step-by-step chemical assembly of a peptide chain on an insoluble solid resin support. The C-terminal amino acid of the target peptide is covalently attached to a resin bead; subsequent amino acids are added one at a time from C-terminus to N-terminus, each protected to prevent unwanted reactions during the addition cycle. When the full sequence is assembled, the peptide is cleaved from the resin and the protecting groups are removed simultaneously, releasing the crude peptide.
The genius of Merrifield’s invention was anchoring the growing chain to a solid support — allowing the resin with the attached peptide to be washed, filtered, and recycled through multiple addition cycles without losing the product. This made automation possible and transformed peptide synthesis from a slow, low-yield laboratory art into a scalable manufacturing process.
The SPPS Cycle: What Happens at Each Step
Why Purification Is Essential: The Deletion Sequence Problem
No coupling reaction is 100% efficient. Even at 99.8% efficiency per step — which requires excellent reagents, technique, and optimised conditions — a 30-residue peptide like semaglutide accumulates approximately 6% total incompletion across all 30 cycles (simplified calculation: 0.998^30 ≈ 0.941 yield). The remaining ~6% is a mixture of deletion sequences — peptides missing one or more amino acids at various positions in the chain.
Deletion sequences often have similar physicochemical properties to the target peptide (they are, after all, very similar structures). They may have partial biological activity, different activity, or no activity — but they are impurities that must be removed before the product meets research-grade quality standards. This is why preparative HPLC purification is not optional — it is essential for achieving ≥99% purity from SPPS crude product.
Why the manufacturer matters for deletion sequence removal
A direct manufacturer controls the SPPS process, the purification method, and the analytical verification. A reseller receives a finished product and has no visibility into the synthesis conditions, the crude purity before purification, or the purification method used. For research requiring ≥99% purity with documented deletion sequence removal, direct manufacturer sourcing with batch-level COA is the only way to have confidence in what you are working with.
Preparative HPLC Purification
The crude peptide mixture from SPPS cleavage contains the target peptide plus deletion sequences, oxidation products, protecting group remnants, and resin-derived impurities. Preparative HPLC separates these by their differential interaction with a reverse-phase stationary phase (typically C18) under a mobile phase gradient (water/acetonitrile with 0.1% TFA or formic acid).
In preparative HPLC, the crude peptide solution is loaded onto a large-diameter column (typically 50–250mm ID vs 4.6mm for analytical) and eluted under a shallow gradient designed to separate the target peptide from adjacent deletion sequences. Fractions are collected and analysed by analytical HPLC; fractions meeting the purity threshold (≥99% peak area) are pooled, and the rest are discarded or recycled. The pooled purified fractions are then concentrated and lyophilized to produce the final product.
Analytical Verification: HPLC + Mass Spectrometry
After preparative purification, every QSC batch undergoes two independent analytical tests before release:
Analytical HPLC: Confirms final purity by peak area integration. The target peptide peak area as a percentage of total peak area must meet ≥99%. The chromatogram is included in the batch COA — it is the primary evidence of purity.
Mass spectrometry (MS): Confirms the molecular weight of the target peak matches the theoretical molecular weight of the target peptide. This is identity verification independent of purity. A peptide could be 99% pure but be the wrong compound if a synthesis or purification error occurred — MS catches this. For chemically modified peptides (CJC-1295 No DAC with four DPP-IV resistance substitutions, GHRP-2 with D-amino acid configuration, Thymosin Alpha-1 with N-terminal acetylation), MS is particularly critical because HPLC alone cannot confirm correct chemical identity.
Both results are published in the batch COA on the QSC product page, independently verifiable via Janoshik.
QSC’s Manufacturing Capability at a Glance
| Capability | QSC | Typical reseller |
|---|---|---|
| SPPS synthesis | In-house automated synthesisers at Qingdao facility | Not applicable — sources from manufacturers |
| Preparative HPLC purification | In-house — controls purification conditions per batch | Not applicable — receives purified product |
| Analytical HPLC verification | In-house — every batch | Depends on manufacturer’s testing |
| Mass spectrometry | In-house — every batch | Depends on manufacturer’s testing |
| Batch traceability | Full — from resin loading to lyophilized product | Limited — black box between source and sale |
| Custom synthesis | Yes — custom sequences on request | Not possible — catalog only |
| Janoshik independent verification | Yes — every batch, publicly searchable | Rare — generally not offered |
Frequently Asked Questions
What is solid-phase peptide synthesis (SPPS)?
Solid-phase peptide synthesis (SPPS) is the chemical process used to build peptide chains by sequentially adding protected amino acids to a growing chain anchored to an insoluble solid resin support. Developed by Robert Bruce Merrifield in 1963 (Nobel Prize, 1984), SPPS revolutionised peptide synthesis by allowing stepwise chain assembly with the growing peptide attached to a solid support — making each cycle of addition, deprotection, and washing straightforward and automatable. SPPS is the universal manufacturing method for research peptides.
What is the difference between Fmoc and Boc SPPS?
Fmoc (fluorenylmethyloxycarbonyl) and Boc (tert-butyloxycarbonyl) refer to the protecting group chemistry used on the alpha-amino group of each amino acid during synthesis. Fmoc is cleaved under mild basic conditions (piperidine); Boc is cleaved under acidic conditions (TFA, then HF for final cleavage). Modern peptide manufacturing predominantly uses Fmoc chemistry because it avoids the corrosive HF required for final Boc resin cleavage and is compatible with a wider range of side-chain protecting groups. QSC uses Fmoc SPPS.
Why does solid-phase synthesis produce deletion sequences?
Deletion sequences are incomplete peptides missing one or more amino acids — formed when a coupling step is incomplete and the next amino acid adds to an unreacted site. Even high-efficiency coupling reactions (>99.5% per step) produce measurable deletion impurities across a 15–30 residue sequence due to accumulated incomplete reactions. This is why preparative HPLC purification after synthesis is essential — to separate the target peptide from the deletion sequence impurities that SPPS inevitably generates.
What is the difference between a peptide manufacturer and a peptide reseller?
A peptide manufacturer synthesises peptides in-house using SPPS equipment, HPLC purification systems, and analytical testing instruments. A reseller purchases finished peptides from manufacturers and repackages or relabels them for sale. QSC is the direct manufacturer — every peptide sold on qsc-eu.com is synthesised at QSC’s Qingdao facility and never touches a third-party supply chain.
How does preparative HPLC purification work?
Preparative HPLC (high-performance liquid chromatography) separates peptide components by their differential interaction with a stationary phase (typically C18 reverse-phase) under a mobile phase gradient. The crude peptide mixture from SPPS is loaded onto a large-scale preparative column; components elute at different times based on their hydrophobicity. Target fractions — those containing the pure target peptide — are collected; fractions containing deletion sequences, oxidation products, or protecting group remnants are discarded. The collected fractions are then analysed by analytical HPLC to confirm purity meets the ≥99% specification.
BPC-157 · Semaglutide · CJC-1295 · Tirzepatide · TB-500